Biogen set to build new gene therapy manufacturing site

By The Science Advisory Board staff writers

March 4, 2021 -- Biogen is planning to build a new manufacturing facility spanning 175,000 sq ft at its base in Research Triangle Park, NC, to support development of its pipeline of gene therapies.

Biogen currently employs a total of approximately 1,900 staff at Research Triangle Park locations and plans to fill 90 new positions. The new facility, which is being created with funding of $200 million, is expected to be up and running by 2023.

Biogen's gene therapy pipeline assets include BIIB111 (timrepigene emparvovec), which is in phase III development for the rare retinal genetic disease choroideremia, and BIIB112 (formerly called NSR-RPGR), which is in phase II for X-linked retinitis pigmentosa.

ViGeneron, Biogen to develop AAV-based gene therapies for eye disease
ViGeneron and Biogen have signed a global collaboration and licensing agreement to develop and commercialize gene therapy products based on adeno-associated...
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...

Copyright © 2021

Glasgow International Health Festival
January 25-26, 2023
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter